ArticleThe American journal of pathology1990
Smooth muscle differentiation in scleroderma fibroblastic cells.
Article in The American journal of pathology, 1990. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 103 citations in OpenAlex.
- Fibroblast PI3K/AKT signaling and extracellular matrix homeostasis: mechanisms, targets, and delivery challenges.Frontiers in cell and developmental biology · 2025Review
- The Crosstalk between N-Formyl Peptide Receptors and uPAR in Systemic Sclerosis: Molecular Mechanisms, Pathogenetic Role and Therapeutic Opportunities.International journal of molecular sciences · 2024Article
- Back to the future: targeting the extracellular matrix to treat systemic sclerosis.Nature reviews. Rheumatology · 2023Review
- Spatial frequency domain imaging for the assessment of scleroderma skin involvement.Biomedical optics express · 2023Article
- Anti-fibrotic effect of a selective estrogen receptor modulator in systemic sclerosis.Stem cell research & therapy · 2022Article
- Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases.Science advances · 2022Article
- Unraveling SSc Pathophysiology; The Myofibroblast.Frontiers in immunology · 2018Review
- Calcium Signaling in the Ventricular Myocardium of the Goto-Kakizaki Type 2 Diabetic Rat.Journal of diabetes research · 2018Review
- An Autotaxin/Lysophosphatidic Acid/Interleukin-6 Amplification Loop Drives Scleroderma Fibrosis.Arthritis & rheumatology (Hoboken, N.J.) · 2016Article
- Investigation of the association between Rho/Rho-kinase gene polymorphisms and systemic sclerosis.Rheumatology international · 2016Article
- Targeting the myofibroblast genetic switch: inhibitors of myocardin-related transcription factor/serum response factor-regulated gene transcription prevent fibrosis in a murine model of skin injury.The Journal of pharmacology and experimental therapeutics · 2014Article
- Extracellular matrix proteins and displacement of cultured fibroblasts from duodenal biopsies in celiac patients and controls.Journal of translational medicine · 2013Article
- Genomic differences distinguish the myofibroblast phenotype of distal lung fibroblasts from airway fibroblasts.American journal of respiratory cell and molecular biology · 2011Article
- Scleroderma-like properties of skin from caveolin-1-deficient mice: implications for new treatment strategies in patients with fibrosis and systemic sclerosis.Cell cycle (Georgetown, Tex.) · 2011Article
- Alteration of fibroblast phenotype by asbestos-induced autoantibodies.Journal of immunotoxicology · 2011Article
- Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of lysophosphatidic acid receptor 1 in a mouse model of scleroderma.Arthritis and rheumatism · 2011Article
- The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab.Rheumatology (Oxford, England) · 2010Article
- Shared expression of phenotypic markers in systemic sclerosis indicates a convergence of pericytes and fibroblasts to a myofibroblast lineage in fibrosis.Arthritis research & therapy · 2005Article
- Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts.Molecular biology of the cell · 2004Article
- Thy-1 expression in human fibroblast subsets defines myofibroblastic or lipofibroblastic phenotypes.The American journal of pathology · 2003Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Using antibodies to alpha-smooth muscle actin and desmin on paraffin-embedded formalin-fixed tissue sections, the authors demonstrate that fibroblastic cells of localized and systemic scleroderma lesions express features of smooth muscle differentiation. Eleven of eleven skin specimens of systemic sclerosis patients and two of four skin specimens of localized scleroderma displayed the presence of fibroblasts expressing alpha-smooth muscle actin, a cell population that predominated in areas of prominent collagen deposition. A similar fibroblastic phenotype was found in the esophagus, the liver, and the lung specimens obtained from four patients who died of progressive systemic sclerosis. Immunostaining for desmin, performed on adjacent tissue sections, demonstrated that a minority of these fibroblastic cells present in skin and visceral lesions contained this protein. The authors' observations indicate that scleroderma fibroblasts are phenotypically related to the stromal cells previously identified in hypertrophic scars, fibromatoses, and desmoplasia; they might provide novel criteria for the characterization of scleroderma lesions and help to identify the factors responsible for phenotypic modulations in fibroblastic cells.
Indexed as
Identifiers
1698026PMC1877526W189098761What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.